Abstract: A Delivery System for delivery of an Active Component is provided. The Delivery System comprises a Delivery Matrix and an Active Component. The Delivery Matrix has one or both of (i) a Cationic Component; and (ii) a Matrix Forming Substance. The Cationic Component has one or both of: (i) a cationic polymer or cationic copolymer, and (ii) a positively charged non-polymeric compound or composition. The Active Component comprises a cationic bioactive. The Delivery Matrix has a mEq amount of positive charge which is equal to or exceeds the mEq amount of positive charge of the Active Component. The Delivery Matrix may comprise chitosan, or other biopolymers, synthetic polymers, matrix polymers and large molecules, which themselves are matrix forming, or are combined with a Matrix Forming Substance and one or more other Cationic Components to form the positively charged Delivery Matrix.

Abstract: A self-adhesive film for covering at least a portion of a surface of three-dimensional (3D) objects such as primary medical devices, body tissues, or anatomical structures is described. When wrapped around a three-dimensional object a consistent adhesive bond between the overlapping layers of the self-adhesive film is created, independent of the substrate material of the 3D object surface. The self-adhesive film is capable of delivering actives, such as antimicrobials, drugs, and other biologically active agents to the 3D object, and also in the vicinity of the 3D object and/or adjacent tissue. Various self-adhesive film designs and methods for delivering one or multiple active agents with various controlled release modes, are described.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: Elutable coatings and materials comprising protein resistant polymer components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus. Medical devices formed from elutable materials comprised of protein resistant polymer components and bioactive agents are also disclosed. The elutable materials comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus.

Abstract: Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.

Abstract: A method for coimmobilizing two or more biomolecules on a substrate in a defined ratio is disclosed. The method uses a copolymer conjugated to a number, N, of different types of oligonucleotides. The copolymer can be adsorbed to the surface of the substrate. N types of oligonucleotides complementary to the copolymer-bound oligonucleotides can be conjugated to N types of biomolecules. The types of the copolymer-bound oligonucleotides can be mixed in a defined ratio then adsorbed to the surface. The biomolecule-bound complementary oligonucletides can be conjugated to the copolymer-oligonucleotides to create a substrate with the biomolecules coimmobilized in a defined ratio. The invention also relates to a substrate prepared by the method of the invention.

Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: The present invention is directed to a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces. The composition is a biomolecule conjugated end-group activated polymer (EGAP). The biomolecule conjugated EGAP can be put to numerous uses including cell adhesion, cell growth, cell sorting, and other biological assays.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.

Abstract: A method for coimmobilizing two or more biomolecules on a substrate in a defined ratio is disclosed. The method uses a copolymer conjugated to a number, N, of different types of oligonucleotides. The copolymer can be adsorbed to the surface of the substrate. N types of oligonucleotides complementary to the copolymer-bound oligonucleotides can be conjugated to N types of biomolecules. The types of the copolymer-bound oligonucleotides can be mixed in a defined ratio then adsorbed to the surface. The biomolecule-bound complementary oligonucletides can be conjugated to the copolymer-oligonucleotides to create a substrate with the biomolecules coimmobilized in a defined ratio. The invention also relates to a substrate prepared by the method of the invention.

Abstract: The present invention is directed to a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces. The composition is a biomolecule conjugated end-group activated polymer (EGAP). The biomolecule conjugated EGAP can be put to numerous uses including cell adhesion, cell growth, cell sorting, and other biological assays.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.